Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

allogeneic gene-edited CD33-knockout hematopoietic stem and progenitor cells

A preparation of human allogeneic hematopoietic stem and progenitor cells (HSPCs) that are ex-vivo gene-edited to remove the cluster of differentiation 33 (CD33) antigen, that can potentially be used to improve hematopoietic recovery after hematopoietic cell transplantation (HCT) and CD33-targeting therapy. Upon administration, allogeneic gene-edited CD33-knockout HSPCs increase and restore the number of HSPCs, which may prevent or decrease infection and other complications of HCT and chemotherapy-induced neutropenia (CIN). The removal of CD33 protects the agent from the cytotoxic effects of CD33-targeted agents administered after HCT.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic CD33KO-HSPC
allogeneic gene-edited CD33-depleted HSCs
allogeneic gene-edited CD33-knockout HSPCs
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search